Abstract: Nanotechnology provides promising possibilities for several biomedical and pharmaceutical applications in the medical industry. Nanostructures play a major role in the recent strategies of technology suitable for novel drug applications. In this work, clindamycin phosphate (CliP) (topical anti-inflammatory drug), xanthan gum (XaG) (biopolymer) and ZnO (zinc oxide) (nanoparticle) nanostructures were synthesized using the sonochemical technique at room temperature. The characterization of the clindamycin phosphate-xanthan gum/ZnO (CliP-XaG/ZnO) nanostructure has been carried out by Fourier transform infrared (FTIR) and X-ray diffraction (XRD). The spectroscopic experiments elucidated the in vitro mechanism of drug delivery system at different pH media (1.2 and 7.4). In this study, the concentration of the drug in the solution was analyzed by UV-Vis spectrophotometric method and detailed error analysis were performed. The Higuchi gave the best correlation with the experimental data. The swelling behavior of the nanostructure was studied. The percentage of the swelling ratio of XaG/ZnO exerted a more significant effect than XaG at pH 1.2 and pH 7.4. The results show that the capacity of XaG / ZnO can be preferred as a novel topical anti-inflammatory drug carrier.
INTRODUCTION
In recent years, novel nanoscale materials (10 to 100 nm) are significantly used as a bio-based nanocarrier drug (nanocapsules, nanospheres, micelles, liposomes, and hydrogels) in pharmaceutical technology via storage/delivery controllable mechanism in the therapeutic application. Nanocarrier drug delivery is a progressive strategy of controlled delivery formulations and next generation of therapeutics and it develops with biocompatibility, bioavailability, targeting, and biodistribution because it has many fascinating advantages, such as reduced drug dosage, improved solubility, increased drug loading capacity, low cost, reduced unwanted chemo-toxicity, increased drug-circulation times, and minimum side effects. Metal oxide-based nanocarriers were discovered to be potent for the rising of bioavailability and biocompatibility of poorly aqueous soluble drugs and targeting (1) (2) (3) .
Biopolymers such as chitosan (4) , gelatin (5), alginate (6) , xanthan gum (7), gum ghatti (8) , and tragacanth gum (9) have been used in drug delivery mechanism owing to their excellent benefits such as biodegradability, nontoxicity, and eco-friendliness. They are employed in a great range of usages such as antibacterial agents, sensor, adsorbent, catalysis, a drug carrier, etc. (10). Physico-chemical properties can be obtained by incorporating an inorganic substance (transporting therapeutic agents) such as metal oxide nanoparticles (11), clay minerals (12), into the biopolymer matrices (13-17). Most drug carriers for drug delivery systems may cause toxicity and immune effects against carriers or therapeutic agents (18) .
Xanthan gum is a linear water-soluble extracellular polysaccharide with trisaccharide provided primarily from the bacterium xanthomonas campestris and has significant properties in the delivery systems, due to its biocompatible, biodegradable and non-toxic features (19) (20) (21) . This study focused on the preparation of XaG/ZnO with a controlled CliP delivery kinetics and error analysis. A CliP has an amide, an amine, and a phosphate group and is used as an antibiotic for anaerobic bacterial infections (22-23).
The primary aims of the study were to elucidate the effects of pH-sensitive XaG /metal oxide on the pharmacokinetic properties of a nanostructure, and to determine how changing the efficiency of the drug can effect in vitro drug delivery profiles. XaG was encapsulated on the surface of ZnO nanoparticles to obtain a new drug carries, and then a drug loading such as CliP was performed. The effects of ZnO nanoparticles on in vitro drug delivery profiles were studied. It was assumed that adding of ZnO nanoparticles was possible to change the anti-inflammatory drug delivery mechanism. 
EXPERIMENTAL SECTION

Materials
Swelling behavior
The swelling properties of the samples were studied at pH of 1.2 and 7.4 at 37 °C. 0.1 g of dried samples were immersed in a 50 mL solution for 6 h to reach swelling equilibrium. The swelling ratio (25-26) of nanostructures was calculated by the following formula (Eq. 1):
(Eq. 1) :the weight of the swollen sample :the weight of the dry sample
Kinetic study of drug delivery
In order to explain the efficacy of the nanostructure, a study of their delivery kinetics is of a major role. The kinetic model for proper the drug delivery mechanism results support to define the delivery profiles. There are several kinetic models, which calculate the overall delivery of drug from the carrier. Generally, five groups are used to understand the controlled kinetics of drug delivery mechanisms such as (Table 1) , and model-independent approach. The main difference between model-independent approach (MIA) and model-dependent approach (MDA) lies in the fact that, while MIA can be calculated from the mean residence time of the drug in the dosage form, the latter requires prior adjustment of the data to a model that describes its temporal evolution. Model-dependent methods are based on different mathematical equations, are very useful to describe the release profile (27) (28) (29) (30) (31) (32) (33) (34) (35) . 
RESULTS AND DISCUSSION
Swelling behavior
In drug delivery mechanisms the delivery rate of the pH-sensitive drug is changed with several different parameters as the swelling ratio, drugmatrix effect, amount of sample, pH, viscosity, and the initial concentration. The viscosity and pH of XaG with different concentration (0.01-0.05 g/50 mL) and the swelling ratio (SR) of XaG and Xa/ZnO in different pH buffer solutions are shown in Fig. 2-4 . This result was based on the electrostatic repulsive force between functional groups and was related to the ZnO has moved as an added crosslinking agent (36) .
Drug delivery studies
The drug delivery kinetic models for the nanostructure were applied in buffer solutions (pH 1.2 and 7.4) at 37±0.5 °C with continuous stirring for 6 h. As shown in Figure 1 , the drug delivery shows a typical pH-sensitive delivery proceeding: faster in neutral and slower in the acidic environment and coherent with the experimental data reported by Honglin Luo and co-workers (37).
In this study, to comprehend the drug delivery kinetic mechanism, the results were examined with different kinetic models such as zero-order kinetics, first-order kinetics, Higuchi model, KorsmeyerPeppas model (Power law), Hixson Crowell model or cube root law and Baker Lonsdale model. Kinetic models emphasizing on different release phenomena were used to fit the drug release profile with the aid of Origin 8 software (Table 2) .
In this study, the drug delivery profiles could be best explained by the Higuchi model (R 2 = 0.936-0.981). The XaG (2.5 g/L) and XaG/ZnO (2.5 g/L) exhibited Qt (mg/g) of 495 and 597, respectively during the initial 6 h of equilibration in neutral medium (Figs. 5-6) . These values for each model Table 2 . It is shown that the delivery kinetics are changed with the addition of ZnO nanoparticles which exhibited a major effect on the rate of drug delivery. Such results of drug delivery are based on the higher surface area and distribution of nanoparticles. Morphology and structure XRD analysis XRD analysis was performed to understand the morphological characteristics of a nanostructure. The XRD patterns of the XaG/ZnO and CliPXaG/ZnO were shown in Figure 7 . The size of the ZnO nanoparticle was determined using Scherr's equation (38 
FTIR analysis
The chemical interactions between drug and XaGZnO nanoparticles were studied by FTIR analysis (Figure 8 ). In FTIR spectra, all the characteristic peaks of XaG were observed at 3267 cm −1 (-OH), at 1594.4 cm −1 (C=O stretching) and at 1369.7 cm −1 (C-H stretching) peaks. FTIR spectrum of XaG-ZnO was found a very intense band below 500 cm −1 related to the stretching vibration of ZnO bond and was observed at 1690.6 cm 
SEM analysis
The Scanning electron microscope (SEM) micrographs performed on the internal structure was used to observe the distribution of the ZnO particles in the XaG and Clip-XaG (Fig.9) . It was monitored that the hydroxides on the surface of the ZnO particles tended to interact with XaG as a cubic structure at a diameter larger than 443 nm and to interact with Clip-XaG as a spherical structure. And also a relatively well dispersion of ZnO nanoparticles in drug-polymer matrix was observed. The experimental results showed that the drug-polymer matrix encapsulated some of the ZnO particles through van der Waals coagulates. The SEM-EDX mapping of Zn, C and O elements on the surface of the samples shown in Figure 10 approve the dispersal of ZnO nanoparticles and the formation of nanostructures. 
Error analysis methods of kinetic models
The application of R 2 is not enough to understand linear drug delivery kinetic models, which evaluates the distinction between experimental and theoretical data. Therefore, we calculated five error analysis methods for identifying of model parameters in this study which were the sum of squares of errors (SSE), The hybrid fractional error function (HYBRID), Marquart's percentage standard deviation (MPSD), The average relative error (ARE), and the sum of the absolute errors (EABS), respectively ( 
MPSD (43) ARE (44) EABS (45) qe,meas: measured capacity, qe, cal:calculated capacity, n: number of data points p: number of parameters.
In this study, we understand that the most clear result from these models is the Higuchi kinetic model in the lowest amounts for the error parameters (Table 4 ) and therefore fits the data better than the rest of the drug delivery kinetic models.
CONCLUSIONS
Comparison of the drug delivery rate profiles of XaG/ZnO by using different types of models showed the highest Qt (mg/g) of the drug carrier at pH 7.4. The parameters of a kinetic model are that the kinetic mechanism displays just diffusion controlled drug delivery from non-degradable panels, the drug is first distributed in a homogeneous phase. The experimental data show that the capacity of XaG/ZnO can be preferred as a novel topical anti-inflammatory drug carrier. 
